CARTISTEM®

Market Approval by MFDS in January 2012100%
100%
Completion of US FDA phase 1/2a clinical trial60%
60%
Approval of Phase 2 clinical trial by PMDA & MHLW, Japan67%
67%

Treatment of repetitive and/or traumatic cartilage degeneration including Degenerative Osteoarthritis(OA) without age limit.

CARTISTEM® – allogeneic umbilical cord blood-derived mesenchymal stem cells, is used for the treatment of knee cartilage defects in patients with Osteoarthritis (with ICRS grade* IV cartilage defect) caused by degeneration or repetitive trauma.

*ICRS grade : A diagnostic criteria used for grading the severity of cartilage defect. Grade IV is the most severe stage with no visible cartilage remaining on the area of defect.

· Product :CARTISTEM®
(human Umbilical Cord Blood-derived
Mesenchymal Stem Cells)
· Manufacturer :MEDIPOST Co., Ltd.
· Indication :Treatment of repetitive and/or
traumatic cartilage degeneration
including Degenerative Osteoarthritis
(with ICRS grade IV cartilage defect)
without age limit.
· Route of Administration
& Dosage :
Surgical administration at
2.5 x 106 cells/500㎕/cm2
(size of knee cartilage defects).

Commercialization of CARTISTEM®
CARTISTEM® has been market-approved with Biologics License Application(BLA) for commercial sale by the Ministry of Food & Drug Safety(MFDS) in January 2012.

Menu